Related Experiment Video

Updated: May 22, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Lestaurtinib inhibits histone phosphorylation and androgen-dependent gene expression in prostate cancer cells

Jens Köhler1, German Erlenkamp, Adrien Eberlin

  • 1Albert-Ludwigs-University Freiburg, Institute of Pharmaceutical Sciences, Albertstrasse, Freiburg, Germany.

Plos One
|April 26, 2012
PubMed
Abstract

Insights

Lestaurtinib potently inhibits protein kinase C related kinase 1 (PRK1) in vitro and in vivo. This epigenetic drug candidate also reduces histone phosphorylation and androgen-dependent gene expression in prostate cancer cells.

Area of Science:

  • Epigenetics and molecular pharmacology.
  • Cancer biology and drug discovery.

Background:

  • Epigenetics involves heritable gene expression changes without altering DNA sequence.
  • Histone posttranslational modifications are key epigenetic regulators.
  • Protein kinase C related kinase 1 (PRK1/PKN1) regulates androgen receptor signaling via histone H3 phosphorylation.

Purpose of the Study:

  • To identify novel inhibitors of PRK1.
  • To investigate the effects of PRK1 inhibition on epigenetic regulation and gene expression.
  • To explore the therapeutic potential of PRK1 inhibitors in prostate cancer.

Main Methods:

  • Focused library screening to identify PRK1 inhibitors.
  • 3D modeling and molecular docking to analyze drug-target interactions.
  • Evaluation of histone H3 threonine phosphorylation and androgen-dependent gene expression in prostate cancer cells.

Main Results:

  • Lestaurtinib (CEP-701) identified as a potent PRK1 inhibitor.
  • Molecular docking revealed key interactions between lestaurtinib and PRK1.
  • Lestaurtinib significantly inhibited histone H3 threonine phosphorylation and androgen-dependent gene expression in cell culture.

Conclusions:

  • Lestaurtinib demonstrates potent inhibition of PRK1 activity.
  • The study reveals a novel effect of PRK1 inhibition on epigenetic regulation and gene expression.
  • Findings have implications for understanding lestaurtinib's clinical activity and developing future PRK1-targeted therapies.

More Related Videos

An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Assays for Validating Histone Acetyltransferase Inhibitors09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...